CAMBRIDGE, Mass. In a note to investors, the firm issued a new rating of Sell. Meanwhile, the company's lead drug candidate is expected to begin a phase 1 clinical trial in the second half of 2020.
Multiple other drug candidates are expected to earn regulatory permission in 2021 for clinical trials. , March 31, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced that the U.S.CAMBRIDGE, Mass. The average price we get from analysts is $28.05 which is $6.65 above current price. , June 02, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced today the pricing of an underwritten public offering ofCompany to Present Three Oral and Two Poster Presentations on In Vivo and Engineered Cell Therapy Pipeline Programs CAMBRIDGE, Mass. Using CRISPR/Cas9 technology, Intellia Therapeutics is developing revolutionary genome editing therapies to cure genetic diseases with simple, targeted treatments. , April 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) has named David Lebwohl , M.D., as its new executive vice president and chief medical officer. The analysts previously had rating of Hold.
In oppose to the moving average for the last 50 days, trading by +66.04% upper at the present time.NTLA stocks went up by 1.90% for the week, with the monthly jump of 8.59% and a quarterly performance of 97.49%, while its annual performance rate touched 37.33%. Learn about financial terms, types of investments, trading strategies and more.View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Intellia Therapeutics (NASDAQ:NTLA) is a biotech company that focuses on gene editing, a relatively new technology that could allow scientists …
Equity return holds the value -40.90%, with -32.50% for asset returns.In the course of the last 5 trading sessions, NTLA went up by +1.90%, which changed the moving average for the period of 200 days to the total of +50.27% of gains for the stock in comparison to the 20-day moving average settled at $20.83. Intellia Therapeutics, Inc. (NASDAQ: NTLA) The 36 Months beta value for NTLA stocks is at 1.73, while of the analysts out of 0 who provided ratings for Intellia Therapeutics, Inc. stocks as a “buy” while as overweight, rated it as hold and as sell.
Latest News. The simple moving average for the period of the last 20 days is 5.54% for NTLA stocks with the simple moving average of 49.12% for the last 200 days.Many brokerage firms have already submitted their reports for NTLA stocks, with Oppenheimer repeating the rating for NTLA shares by setting it to “Outperform”. Before Intellia, David was chief medical officer at Semma, Therapeutics Inc., a subsidiary of Vertex Pharmaceuticals Inc., where he was leading the company’s regenerative medicine efforts using stem-cell-derived pancreatic islets to cure type I diabetes. Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Stock Market Daily: Intellia Therapeutics stock has undergone multiple analysts rating changes in the recent past. The predicted price for NTLA socks in the upcoming period according to Oppenheimer is $220 based on the research report published on February 28, 2020.After a stumble in the market that brought NTLA to its low price for the period of the last 52 weeks, Intellia Therapeutics, Inc. was unable to take a rebound, for now settling with -9.54% of loss for the given period.LEONARD JOHN M., the President and CEO of Intellia Therapeutics, Inc., sold 5,000 shares at the value of $21.83 during a trade that took place back on Jun 03, which means that LEONARD JOHN M. is holding 467,352 shares at the value of $109,150 based on the most recent closing price.The current profitability levels are settled at -246.78 for the present operating margin. Want to see which stocks are moving? Find the latest news headlines from Intellia Therapeutics, Inc. Common Stock (NTLA) at Nasdaq.com.
View our full suite of financial calendars and market data tables, all for free.Learn everything you need to know about successful options trading with this three-part video course.Receive a free world-class investing education from MarketBeat.
Find the latest news headlines from Intellia Therapeutics, Inc. Common Stock (NTLA) at Nasdaq.com.